TScan Therapeutics (TCRX) Net Cash Flow (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Net Cash Flow data on file, last reported at -$24.3 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 0.94% year-over-year to -$24.3 million in Q1 2026; TTM through Mar 2026 was -$26.1 million, a 291.62% decrease from a year earlier, with the FY2025 full-year figure at -$26.3 million, down 157.98% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$24.3 million, down from -$17.1 million in the prior quarter.
• Over the last five years, Net Cash Flow for TCRX reached as high as $101.6 million in Q2 2024 and fell as low as -$109.0 million in Q3 2024.
• Historically, Net Cash Flow has averaged -$9.9 million across 5 years, with a median of -$17.3 million in 2022.
• Across the five-year window, Net Cash Flow slumped 558.42% in 2023 and surged 552.93% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at -$17.3 million in 2022, then retreated by 26.36% to -$21.8 million in 2023, then surged by 308.72% to $45.6 million in 2024, then slumped by 137.52% to -$17.1 million in 2025, then sank by 42.39% to -$24.3 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$24.3 million in Q1 2026, -$17.1 million in Q4 2025, and $112000.0 in Q3 2025.